Development of a smart transformable nanotherapeutic against cancers with acquired resistance to EGFR-targeted therapies caused by MET amplification
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Development of a smart transformable nanotherapeutic against cancers with acquired resistance to EGFR-targeted therapies caused by MET amplification
Principal Institution
Khon Kaen University
Principal Investigator(s) (PI)
Mahalapbutr, Panupong
Project Contact Information
Email: panupma@kku.ac.th
Year(s) Awarded
2024-2029
Country
Thailand
Collaborators
University of California
NIH Partners
NCI
Project Description
The administration of epidermal growth factor receptor (EGFR)-targeted therapies to cancer patients invariably leads to the development of drug resistance, mainly caused by a mesenchymal-epithelial transition (MET) amplification. This innovative research project addresses this issue by rigorously developing smart transformable EGFR/MET-targeting peptide nanoparticles for treatment of cancers with acquired resistance to EGFR-targeted therapies due to MET amplification. The successful completion of this project will not only lead to the creation of new classes of safe and effective targeted nanotherapeutics against cancers but also open avenues for the advancement of functional nanomaterials in biomedical applications.
Related World Regions / Countries
Related Global Health Research Topics